分化型甲状腺癌<sup>18</sup>F-FDG PET显像的临床应用

康玉国

分化型甲状腺癌¹⁸F-FDG PET显像的临床应用

康玉国

文章导航 > 国际放射医学核医学杂志 > 2000, 24 > 6: (264-267)

引用本文:

Citation:

分化型甲状腺癌¹⁸F-FDG PET显像的临床应用

康玉国

610041 四川成都, 华西医科大学附一院核医学科

作者简介: 康玉国(1971-),男,山西太原人,华西医科大学附一院核医学科硕士研究生,主要从事分子核医学研究。;

中图分类号: R817.4

Application of ¹⁸F-FDG PET scan in patients with differentiated thyroid cancer

KANG Yuguo

Department of Nuclear Medicine, The First Affiliated Hospital, WCUMS, Sichuan Chengdu, China
CLC number: R817.4

摘要: 低分化型甲状腺癌细胞摄取碘能力的下降或丧失导致¹³¹IWBS(全身显像)假阴性(约20%),高水平的血清Tg(甲状腺球蛋白)只能说明有分化型甲状腺癌(DTC)的复发或转移,不能确定DTC复发或转移的具体位置,而低分化型甲状腺癌正是DTC病人死亡的主要类型。本文主要探讨¹⁸F-FDG(¹⁸F-氟代脱氧葡萄糖)PET显像在¹³¹I的WBS阴性而血清Tg水平增高的DTC病人中鉴别复发和转移的应用以及评价DTC病人预后的价值,当嗜¹⁸F-FDG肿瘤显示的体积大于125mL或FDG标准摄取值大于10g/mL时,病人的预后不良。
- 分化型甲状腺癌 /
- ¹⁸F-氟代脱氧葡萄糖 /
- 正电子发射断层显像 /
- 预后
Abstract: Poorly differentiated thyroid cancer lesions often lose the ability to concentrate radioactive [¹³¹I] iodine and exhibit increased metabolic activity, as evidenced by enhanced glucose uptake.¹⁸F-FDG PET was able to localize residual and metastatic thyroid cancer lesions in patients with negative diagnostic ¹³¹IWBS and elevated serum thyroglobulin levels, although it uas not sensitve enough to detect mivimal metastatic disea in cervical nodes.multivariate analysis demonstrated that the single strongest predictor of survial was the volume of FDG-avid disease.Subjects with a FDG volume greater than 125mL or with SUV greater than 10g/mL have significantly reduced short survival.

本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Landis S.Murray T, Bolden S, et al.1998 cancer statistics[J].Cancer, 1998, 48:1-31.
[2]	Lind P, Gallowitsch HJ, Mikosch, et al.Comparison of different tracers in the follow up of differentiated thyroid carcinoma[J].Acta Med Austriaca, 1999, 26 (4):115-117.
[3]	Wang W, Macapinlac H, Larson SM, et al.¹⁸F-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)Ⅰ whole body scan and elevated serum thyoglobulin levels[J].J Clin Endocrinol Metab, 1999, 84(7):2291-2302.
[4]	Stokkel MP, Klerk JH, Zeliseen PM, et al.The detection of recurrent differentiated thyroid cancer[J].Eur J Nucl Med, 1999, 26(12):1606-1609.
[5]	Mauro F, Alberto S, Guido V, et al.Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases[J].J Nucl Med, 1998, 39(9):1542-1545.
[6]	Alnafisi NS, Driedger AA, Coates G, et al.FDG PET in papillary thyroid carcinoma[J].J Nucl Med, 2000, 41 (6):1010-1015.
[7]	Chung JK, So Y, Lee JS, et al.Value of FDG PET in papillary thyroid carcinoma with negative ¹³¹I whole-body scan[J].J Nucl Med, 1999, 40(6):986-992.
[8]	Altenvoerde G, Lerch H, Kuwert T, et al.Positron emission tomography with differentiated thyroid carcicinoma, elevated thyroglobin levels, and negative iodine scans[J].Langenbecks Arch Chir, 1998, 383:160-163.
[9]	Dietlein M, Scheidhauer K, Voth F, et al.Follow-up of differentiated thyroid cancer:what is the value of FDG and sestamibi in the diagnostic algorithm?[J].Nuklearmedizin, 1998, 37(1):12-17.
[10]	Huang TS, Chieng PU, Chang CC, et al.Positron emission tomography for detecting iodine-131 nonvisualized metastasis of well-differentiated thyroid carcinoma[J].J Endocrinol Inv, 1998, 21(6):392-398.
[11]	Filesi M, Signore A, Ventroni G, et al.Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases[J].J Nucl Med, 1998, 39(9):1542-1546.
[12]	Grunwald F, Kalicke T, Feine U, et al.Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer[J].Eur J Nucl Med, 1999, 26(12):1547-1552.
[13]	Schlumberger M, Baudin E.Papillary and follicular thyroid carcinoma[J].N Engl JM ed, 338:297-306.
[14]	Lind P, Kumning G, Matschning S, et al.The role of F-18 FDG PET in thyroid cancer[J].Acta Med Austriaca, 2000, 27(2):38-41.
[15]	Wang W, Larson SM, Fazzari M, et al.Prognostic value of [¹⁸F]-2-fluoro-2-deoxy-D-glucose positron emission tomographic scanning in patients with thyroid cancer[J].J Clin Endocrinol Metab, 2000, 85(3):1107-1113.
[16]	Wang W, Larson SM, Fazzari M, et al.Resistance of FDG-PET positive metastatiic thyroid carcinoma leisions to treatment with radioactive iodine[J].Thyroid, 1999, 9(Suppl 1):32
[17]	Feine U, Lietzenmayer R, Hanke JP, et al.Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer[J].J Nucl Med, 1996, 37:1468-1472.

[1]	胡文悦 , 刘娇 , 刘保平 . 分化型甲状腺癌合并桥本甲状腺炎患者血清TgAb水平检测的临床价值. 国际放射医学核医学杂志, 2019, 43(3): 217-222. doi: 10.3760/cma.j.issn.1673-4114.2019.03.004
[2]	韩娜 , 刘新峰 , 司增梅 , 李娇 , 张莹莹 , 王叙馥 . 分化型甲状腺癌¹³¹I治疗后TgAb由阳转阴时间与临床转归的关系. 国际放射医学核医学杂志, 2022, 46(7): 412-418. doi: 10.3760/cma.j.cn121381-202203030-00197
[3]	李林 . ¹⁸F-FDG PET显像在肿瘤学中的应用. 国际放射医学核医学杂志, 2000, 24(6): 254-258.
[4]	张立颖 . ¹⁸F-FDG PET显像在恶性淋巴瘤中的应用. 国际放射医学核医学杂志, 2001, 25(1): 10-12.
[5]	管梁 , 吕中伟 . ¹⁸F-FDG PET显像在鉴别胰腺良恶性肿块中的应用价值. 国际放射医学核医学杂志, 2000, 24(6): 259-263.
[6]	刘道佳 , 吴君心 , 唐明灯 , 林端瑜 , 张杰平 , 李生栩 , 蔡志华 , 吕清湖 . ¹⁸F-FLT PET/CT显像评估复发脑胶质瘤患者预后的价值. 国际放射医学核医学杂志, 2018, 42(5): 403-408. doi: 10.3760/cma.j.issn.1673-4114.2018.05.003
[7]	陈学涛 , 姚稚明 . 术前¹⁸F-FDG PET/CT显像代谢参数在非小细胞肺癌患者预后评估中的应用进展. 国际放射医学核医学杂志, 2020, 44(11): 704-708. doi: 10.3760/cma.j.cn121381-201908030-00090
[8]	钞卫光 , 张晶 , 陆克义 . 分化型甲状腺癌腹盆部¹³¹I显像假阳性分析. 国际放射医学核医学杂志, 2017, 41(5): 370-373. doi: 10.3760/cma.j.issn.1673-4114.2017.05.012
[9]	南楠 , 朱小华 . 分化型甲状腺癌¹³¹I显像假阳性的原因分析. 国际放射医学核医学杂志, 2018, 42(1): 62-68. doi: 10.3760/cma.j.issn.1673-4114.2018.01.012
[10]	史文琴 . PET显像在卵巢癌诊断中的作用. 国际放射医学核医学杂志, 2001, 25(4): 158-160.

点击查看大图

计量

文章访问数: 1122
HTML全文浏览量: 185
PDF下载量: 4

分化型甲状腺癌¹⁸F-FDG PET显像的临床应用

康玉国

作者简介:康玉国(1971-),男,山西太原人,华西医科大学附一院核医学科硕士研究生,主要从事分子核医学研究。

610041 四川成都, 华西医科大学附一院核医学科

收稿日期: 2000-11-21

关键词:

摘要: 低分化型甲状腺癌细胞摄取碘能力的下降或丧失导致¹³¹IWBS(全身显像)假阴性(约20%),高水平的血清Tg(甲状腺球蛋白)只能说明有分化型甲状腺癌(DTC)的复发或转移,不能确定DTC复发或转移的具体位置,而低分化型甲状腺癌正是DTC病人死亡的主要类型。本文主要探讨¹⁸F-FDG(¹⁸F-氟代脱氧葡萄糖)PET显像在¹³¹I的WBS阴性而血清Tg水平增高的DTC病人中鉴别复发和转移的应用以及评价DTC病人预后的价值,当嗜¹⁸F-FDG肿瘤显示的体积大于125mL或FDG标准摄取值大于10g/mL时,病人的预后不良。